ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Jun 28, 2021 15:00 JST
Source:
Avance Clinical
Avance Clinical Appoints Asia Biotech Specialist to Support APAC Growth
ADELAIDE, AUS, Jun 28, 2021 - (ACN Newswire) - Avance Clinical, the leading Australian CRO for international biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient, announced the appointment of Andy Hu as Business Development Manager APAC, to support increasing biotech clinical trial demand from the region.
Andy Hu
Formerly with Informa Pharma Intelligence, the international biopharma data company, Andy will head up the APAC business development program for Avance Clinical.
Andy says the main drivers for Asian biotechs looking to Australia are speed, data quality and access to international regulatory authorities.
"They select Avance Clinical in Australia because its CRO data is accepted by the FDA, and it gives them a rapid pathway for international licensing, investment and ultimately drug approvals," he said.
"I wanted to work with Avance Clinical because it's a mid-sized CRO that offers deep therapeutic experience, expedited timelines, and exceptional support to APAC biotech clients."
Avance Clinical has grown significantly over the past two years with an increasing number of clients coming from APAC to conduct their trials in Australia.
Chief Strategy Officer Ben Edwards said the appointment of Andy Hu will further support growth and strengthen relationships with clients in the region.
"Andy is multilingual, being fluent in English, Mandarin and Korean, and has completed both a Bachelor of Korean Language and Culture as well as a Master of Translation and Interpreting. He will be responsible for developing business across the APAC region to better serve our clients operating in the region," he said.
The Avance Clinical team is attending BIO Digital 2021 virtually and is available on the BIO One-on-One Partnering(TM) platform to discuss the benefits of conducting trials in Australia.
Avance Clinical has recently won the BDO Excellence in Business Award 2021 for rapid managed growth and attracting and nurturing experienced staff in a competitive global environment.
The mid-sized CRO has a reputation for going beyond the industry time and support for Sponsors, and for providing staff the training and resources needed to deliver excellence in clinical research management.
About Avance Clinical
Avance Clinical is the largest specialist Australian CRO delivering quality clinical trials in Australia and New Zealand for international biotechs. Avance Clinical has been delivering CRO services in the region for the past 24 years. Our clients are international biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services. Avance Clinical delivers customised solutions designed around specific client needs rather than a one size fits all approach. As a company we have focussed on state-of-the-art technology and systems across all functional areas to provide our clients with the most effective processes. Medidata, Oracle, and Medrio are just some of our technology partners. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of candidates who demonstrate passion and expertise in their chosen field. Visit
http://www.avancecro.com
for more information.
Recent Awards:
Excellence in Business Award 2021
Frost & Sullivan Asia-Pacific CRO Market Leadership Award 2020
Media Contact:
media@avancecro.com
Source: Avance Clinical
Sectors: BioTech, Healthcare & Pharm, Clinical Trials
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Hitachi Advances Strategic Alliance with Google Cloud to Empower Frontline Workers with Field-Specific AI Agents
Oct 11, 2025 00:58 JST
Honda Issues Integrated Report - "Honda Report 2025"
Oct 11, 2025 00:46 JST
DENSO's Electrification Products Adopted for TOYOTA's New "bZ4X"
Oct 11, 2025 00:21 JST
Newly developed eAxle adopted for TOYOTA's new "bZ4X"
Oct 11, 2025 00:08 JST
MHIET and MHI-TC Complete Delivery of First "COORDY" Controller Providing Optimized Control of Multiple Power Sources
Oct 10, 2025 23:47 JST
Fujitsu migrates service operations virtualization platform used by 3,000 companies to Nutanix and introduces migration support services utilizing proven expertise
Oct 10, 2025 23:25 JST
Anime Tokyo Station: TV Anime 'SPYxFAMILY' Special Exhibition, New Designs Added for Admission Bonus Illustration Cards
Oct 10, 2025 11:30 JST
TANAKA to Provide Medals Expressing Every Runner's Trail through Flowing Curves for the Tokyo Legacy Half Marathon 2025
Oct 10, 2025 03:00 JST
Genequest and Fujitsu uncover new insights into genetics-lifestyle relationships through high-speed, reliable causal AI from Fujitsu Kozuchi
Oct 10, 2025 00:55 JST
Sharp Launches A3 MFPs (BP Series)
Oct 10, 2025 00:50 JST
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony in Shimonoseki for Large Car Ferry HAMANASU
Oct 10, 2025 00:42 JST
Honda Celebrates 30th Anniversary of CR-V
Oct 09, 2025 23:54 JST
DASSAI MOON Project, the World's First Test Brewing of Sake in Space
Oct 09, 2025 23:23 JST
All-New Destinator Wins Gold Award at VMARK Vietnam Design Award 2025
Oct 09, 2025 22:17 JST
Mazda Tests Feasibility of Commercializing Corrosion Resistance Evaluation Service for Coated Components
Oct 09, 2025 21:29 JST
Sumitomo Metal Mining and Toyota Collaborate on Mass Production of Cathode Materials for All-Solid-State Batteries
Oct 09, 2025 20:40 JST
Fujitsu and ARYA develop high-precision AI solution for instant detection of suspicious behavior
Oct 08, 2025 14:39 JST
Toda, JTB and Fujitsu kick off NFT-powered digital transformation project to boost international tourism to Japan
Oct 08, 2025 13:39 JST
Fujitsu and Sony Bank partner to integrate generative AI into core banking system design and development
Oct 08, 2025 13:02 JST
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
Oct 08, 2025 12:03 JST
More Latest Release >>
Related Release
Avance Clinical Appoints Asia Regional Director as Part of Global Expansion Program
July 23 2024 16:00 JST
New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Can Deliver 30% Savings, Halve Timelines and Cut Risks for Biotechs
June 04 2024 22:00 JST
Avance Clinical Expands Specialist CNS, Cardiometabolic, and Rare Diseases CRO Services in Europe with Julius Clinical
May 31 2024 16:00 JST
Avance Clinical Expands Further into APAC with New Clinical Operations in South Korea
May 08 2024 09:00 JST
Avance Clinical Showcases Clinical Excellence at World Orphan Drug Conference in Boston, April 23-25
April 19 2024 16:00 JST
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 Study
March 28 2024 14:42 JST
Avance Clinical CEO Talks with SCRIP about US Biotech Sector "Green Shoots" and a New CRO Report
February 28 2024 08:00 JST
Latest Analysis Reveals 65% of US Biotechs Struggle to Identify Suitable CRO Partner
January 12 2024 16:00 JST
Avance Clinical Invited to Brief 45 Korean Biotechs on Their GlobalReady Drug Development Pathway from Korea and Australia to the US
October 19 2023 09:00 JST
Avance Clinical at ASCO & BIO 2023: Early Phase Oncology Trials Increasingly Elaborate and Demand More Patients
May 30 2023 10:00 JST
More Press release >>